Metyrosine
Tyrosine Hydroxylase Inhibitors
- Drug class
- Tyrosine Hydroxylase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 10
Overview
Plain-language summary, compiled from the cited regulatory records
Metyrosine is a medication classified as a tyrosine hydroxylase inhibitor [1]. It is approved for the treatment of patients diagnosed with pheochromocytoma [1]. Specifically, it is used to prepare patients for surgery, to manage cases where surgery is not an option, and for the ongoing treatment of malignant pheochromocytoma [1]. Metyrosine is not recommended for managing general high blood pressure [1].
This medication is available under various brand names [1]. In the past 12 months, there have been 10 adverse event reports associated with this active ingredient [2]. The most frequently reported adverse events include malignant neoplasm, off-label use, pyrexia, acute myocardial infarction, and adrenal hemorrhage [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | April 14, 2026 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Metyrosine capsules are indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery. 2. Management of patients when surgery is contraindicated. 3. Chronic treatment of patients with malignant pheochromocytoma.
Metyrosine capsules are not recommended for the control of essential hypertension.
How to take
Drug interactions
Known interactions involving Metyrosine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 027f02b1-be49-48… · revised April 14, 2026 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.